In Vivo Testing Center for gonorrhea vaccine and antibody drug in mice
Official title: Core C - in vivo Efficacy Testing (CIIG)
Funded at Henry M. Jackson Fdn for the Adv Mil/med · NIH-11394888 · Data updated 2026-11-12
This NIH grant funds centralized testing of candidate gonorrhea vaccines and an antibody drug conjugate in mouse models to help advance preventions and treatments against antibiotic-resistant gonorrhea.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry M. Jackson Fdn for the Adv Mil/med NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project start | August 12, 2025 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $900,086 |
| NIH project number | 5U19AI189178-02 |
| Project ID | NIH-11394888 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals affected by gonorrhea or at risk of infection, or future trial participants for vaccine or antibody-based therapies once they advance to human studies.
✕Less likely to help
Early-stage animal testing may not directly benefit patients until human trials progress.
What this research studies
If you or a loved one is affected by gonorrhea, this project provides a pathway to faster, safer testing of vaccines and targeted therapies in established mouse models to see how well they stop infection or work with existing antibiotics. The Core C team tests vaccines and antibody-based products in female mouse models of gonorrhea infection, including models with ascending infection and coinfection with Chlamydia, to understand real-world challenges. The research uses vaccines and antibody therapies delivered in different ways to simulate how they might be given to patients and measure efficacy. By generating robust efficacy data in these animal models, the work supports translation to human studies and future clinical testing. This core is designed to streamline and standardize testing across CIIG projects to speed up the development of effective interventions.
Why it matters
Potential benefit: If successful, this work could accelerate the development of vaccines and antibody-based treatments to prevent and treat gonorrhea, potentially reducing infections and antibiotic resistance in people.
How similar studies have gone: Similar animal-testing approaches have successfully advanced candidate vaccines and antibody therapies in infectious disease research, supporting translational potential.
Where this research is happening
-
Henry M. Jackson Fdn for the Adv Mil/med
Bethesda, United States Active
Researchers
- Principal investigator: Jerse, Ann E. — Henry M. Jackson Fdn for the Adv Mil/med
- Study coordinator: Jerse, Ann E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.